去年，辉瑞表现最佳的业务板块Eliquis alliance revenues and direct sales实现营收7.96B美元。United States的营收贡献最高，去年达到37.08B美元。最近一个季度，截至2026-06-28，辉瑞表现最佳的业务板块Eliquis alliance revenues and direct sales实现营收2.42B美元。United States的营收贡献最高，达到8.86B美元。

业务

营业收入

占比

年报

年报

单季报

Eliquis alliance revenues and direct sales

Prevnar family

Vyndaqel family

Comirnaty

Oncology-Ibrance

All other Hospital

All other primary care

Paxlovid

Oncology-Xtandi alliance revenues

Padcev

All other Speciality Care

Nurtec ODT/Vydura

Pfizer CentreOne

Oncology biosimilars

Oncology-All other Oncology

Xeljanz

Abrysvo

Lorbrena

Oncology-Inlyta

Adcetris

Braftovi

Sulperazon

Inflectra/Remsima

Zavicefta

Enbrel (Outside the U.S. and Canada)

Oncology-Bosulif

Tukysa

Aromasin

Genotropin

Orgovyx

octagam

Zithromax

Cresemba

FSME/IMMUN-ticovac

Elrexfio

Cibinqo

Talzenna

Tivdak

Pfizer Ignite

BeneFIX

Premarin Family

BMP2

Oxbryta

Comimaty direct sales and alliance revenues

All other Anti-infectives

Ig Portfolio

Oncology-Zirabev

Oncology - Ruxience

Oncology-Xalkor

Retacrit

Medrol

Somavert

Fragmin

Besponsa

Refacto AF/Xyntha

Oncology-Bavencio alliance revenues

Vfend

Sutent

Nimenrix

Mektovi

Bicillin

Trumenba

Trazimera

Vaccines-Prevnar 13/Prevenar 13

Hospital-All other Hospital

PFIZER CENTREONE

Internal Medicine-All other Internal Medicine

Chantix/Champix

Toviaz

hospita-precedex

Hospital-Zyvox

Inflammation & Immunology (I&I)-All other I&I

Rare Disease-All other Rare Disease

Vaccines-All other Vaccines

Consumer Healthcare Business

Hospital-Pfizer CentreOne

Hospital-EpiPen

Hospital-Panzyga

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Eliquis alliance revenues and direct sales

7.96B(12.72%)

7.37B(11.34%)

6.75B(8.64%)

6.48B(4.44%)

5.97B(13.94%)

4.95B(12.29%)

4.22B(10.57%)

3.43B(8.41%)

Prevnar family

6.49B(10.38%)

6.41B(9.87%)

6.50B(8.33%)

18.93B(12.98%)

--(--)

Vyndaqel family

6.38B(10.20%)

5.45B(8.39%)

3.32B(4.25%)

2.45B(1.68%)

2.02B(4.70%)

1.29B(3.20%)

473.00M(1.19%)

148.00M(0.36%)

Comirnaty

4.37B(6.98%)

5.35B(8.24%)

11.22B(14.37%)

37.81B(25.93%)

--(--)

Oncology-Ibrance

4.12B(6.59%)

4.37B(6.72%)

4.75B(6.09%)

5.12B(3.51%)

5.44B(12.69%)

5.39B(13.39%)

4.96B(12.43%)

4.12B(10.09%)

All other Hospital

4.03B(6.44%)

4.17B(6.42%)

4.51B(5.78%)

4.73B(3.24%)

--(--)

All other primary care

2.86B(4.57%)

2.99B(4.61%)

2.97B(3.80%)

2.47B(1.70%)

--(--)

Paxlovid

2.36B(3.77%)

5.72B(8.80%)

1.28B(1.64%)

6.34B(4.35%)

--(--)

Oncology-Xtandi alliance revenues

2.19B(3.51%)

2.04B(3.14%)

1.66B(2.13%)

1.65B(1.13%)

1.19B(2.77%)

1.02B(2.54%)

838.00M(2.10%)

699.00M(1.71%)

Padcev

1.94B(3.10%)

1.59B(2.45%)

53.00M(0.07%)

--(--)

All other Speciality Care

1.59B(2.54%)

1.49B(2.29%)

1.35B(1.73%)

743.00M(0.51%)

--(--)

Nurtec ODT/Vydura

1.42B(2.28%)

1.26B(1.94%)

928.00M(1.19%)

213.00M(0.15%)

--(--)

Pfizer CentreOne

1.34B(2.14%)

1.15B(1.76%)

1.27B(1.63%)

1.34B(0.92%)

--(--)

Oncology biosimilars

1.30B(2.08%)

1.04B(1.60%)

1.41B(1.80%)

1.75B(1.20%)

--(--)

Oncology-All other Oncology

1.13B(1.80%)

1.12B(1.73%)

1.31B(1.68%)

1.85B(1.27%)

238.00M(0.56%)

137.00M(0.34%)

122.00M(0.31%)

395.00M(0.97%)

Xeljanz

1.09B(1.74%)

1.17B(1.80%)

1.70B(2.18%)

1.80B(1.23%)

2.46B(5.73%)

2.44B(6.05%)

2.24B(5.62%)

1.77B(4.35%)

Abrysvo

1.03B(1.65%)

755.00M(1.16%)

890.00M(1.14%)

--(--)

Lorbrena

1.02B(1.63%)

731.00M(1.13%)

539.00M(0.69%)

343.00M(0.24%)

266.00M(0.62%)

204.00M(0.51%)

115.00M(0.29%)

11.00M(0.03%)

Oncology-Inlyta

923.00M(1.48%)

978.00M(1.51%)

1.04B(1.33%)

1.00B(0.69%)

1.00B(2.34%)

787.00M(1.95%)

477.00M(1.20%)

298.00M(0.73%)

Adcetris

907.00M(1.45%)

1.09B(1.68%)

56.00M(0.07%)

--(--)

Braftovi

716.00M(1.14%)

607.00M(0.93%)

477.00M(0.61%)

456.00M(0.31%)

187.00M(0.44%)

160.00M(0.40%)

48.00M(0.12%)

--(--)

Sulperazon

653.00M(1.04%)

637.00M(0.98%)

757.00M(0.97%)

786.00M(0.54%)

683.00M(1.59%)

618.00M(1.53%)

684.00M(1.71%)

613.00M(1.50%)

Inflectra/Remsima

646.00M(1.03%)

509.00M(0.78%)

490.00M(0.63%)

532.00M(0.36%)

657.00M(1.53%)

659.00M(1.64%)

625.00M(1.57%)

642.00M(1.57%)

Zavicefta

638.00M(1.02%)

586.00M(0.90%)

511.00M(0.65%)

412.00M(0.28%)

413.00M(0.96%)

212.00M(0.53%)

108.00M(0.27%)

46.00M(0.11%)

Enbrel (Outside the U.S. and Canada)

627.00M(1.00%)

690.00M(1.06%)

830.00M(1.06%)

1.00B(0.69%)

1.19B(2.77%)

1.35B(3.35%)

1.70B(4.26%)

2.11B(5.17%)

Oncology-Bosulif

611.00M(0.98%)

645.00M(0.99%)

645.00M(0.83%)

575.00M(0.39%)

540.00M(1.26%)

450.00M(1.12%)

365.00M(0.91%)

296.00M(0.73%)

Tukysa

463.00M(0.74%)

480.00M(0.74%)

18.00M(0.02%)

--(--)

Aromasin

450.00M(0.72%)

347.00M(0.53%)

301.00M(0.39%)

248.00M(0.17%)

--(--)

Genotropin

446.00M(0.71%)

470.00M(0.72%)

539.00M(0.69%)

360.00M(0.25%)

389.00M(0.91%)

427.00M(1.06%)

498.00M(1.25%)

558.00M(1.37%)

Orgovyx

421.00M(0.67%)

201.00M(0.31%)

120.00M(0.15%)

--(--)

octagam

418.00M(0.67%)

509.00M(0.78%)

245.00M(0.31%)

--(--)

Zithromax

399.00M(0.64%)

480.00M(0.74%)

406.00M(0.52%)

331.00M(0.23%)

278.00M(0.65%)

276.00M(0.69%)

336.00M(0.84%)

326.00M(0.80%)

Cresemba

349.00M(0.56%)

281.00M(0.43%)

195.00M(0.25%)

155.00M(0.11%)

--(--)

FSME/IMMUN-ticovac

319.00M(0.51%)

280.00M(0.43%)

268.00M(0.34%)

200.00M(0.14%)

185.00M(0.43%)

196.00M(0.49%)

220.00M(0.55%)

140.00M(0.34%)

Elrexfio

304.00M(0.49%)

133.00M(0.20%)

10.00M(0.01%)

--(--)

Cibinqo

284.00M(0.45%)

215.00M(0.33%)

128.00M(0.16%)

27.00M(0.02%)

--(--)

Talzenna

182.00M(0.29%)

117.00M(0.18%)

64.00M(0.08%)

48.00M(0.03%)

--(--)

Tivdak

147.00M(0.23%)

131.00M(0.20%)

4.00M(0.01%)

--(--)

Pfizer Ignite

41.00M(0.07%)

82.00M(0.13%)

44.00M(0.06%)

7.00M(--)

--(--)

BeneFIX

--(--)

381.00M(0.59%)

424.00M(0.54%)

425.00M(0.29%)

438.00M(1.02%)

454.00M(1.13%)

488.00M(1.22%)

554.00M(1.36%)

Premarin Family

--(--)

380.00M(0.59%)

397.00M(0.51%)

455.00M(0.31%)

563.00M(1.31%)

680.00M(1.69%)

734.00M(1.84%)

832.00M(2.04%)

BMP2

--(--)

352.00M(0.54%)

338.00M(0.43%)

277.00M(0.19%)

266.00M(0.62%)

274.00M(0.68%)

287.00M(0.72%)

279.00M(0.68%)

Oxbryta

--(--)

201.00M(0.31%)

328.00M(0.42%)

73.00M(0.05%)

--(--)

Comimaty direct sales and alliance revenues

--(--)

11.22B(14.37%)

37.81B(25.93%)

--(--)

All other Anti-infectives

--(--)

1.09B(1.40%)

1.17B(0.80%)

1.45B(3.39%)

1.29B(3.21%)

1.40B(3.50%)

1.66B(4.07%)

Ig Portfolio

--(--)

584.00M(0.75%)

491.00M(0.34%)

--(--)

Oncology-Zirabev

--(--)

424.00M(0.54%)

562.00M(0.39%)

444.00M(1.04%)

143.00M(0.36%)

1.00M(--)

--(--)

Oncology - Ruxience

--(--)

390.00M(0.50%)

458.00M(0.31%)

491.00M(1.15%)

170.00M(0.42%)

-1.00M(--)

--(--)

Oncology-Xalkor

--(--)

374.00M(0.48%)

465.00M(0.32%)

493.00M(1.15%)

544.00M(1.35%)

530.00M(1.33%)

524.00M(1.28%)

Retacrit

--(--)

340.00M(0.44%)

394.00M(0.27%)

444.00M(1.04%)

386.00M(0.96%)

225.00M(0.56%)

82.00M(0.20%)

Medrol

--(--)

339.00M(0.43%)

328.00M(0.22%)

432.00M(1.01%)

402.00M(1.00%)

469.00M(1.18%)

493.00M(1.21%)

Somavert

--(--)

267.00M(0.34%)

268.00M(0.18%)

277.00M(0.65%)

277.00M(0.69%)

264.00M(0.66%)

267.00M(0.65%)

Fragmin

--(--)

238.00M(0.30%)

269.00M(0.18%)

305.00M(0.71%)

252.00M(0.63%)

253.00M(0.63%)

293.00M(0.72%)

Besponsa

--(--)

236.00M(0.30%)

219.00M(0.15%)

--(--)

Refacto AF/Xyntha

--(--)

230.00M(0.29%)

239.00M(0.16%)

304.00M(0.71%)

370.00M(0.92%)

426.00M(1.07%)

514.00M(1.26%)

Oncology-Bavencio alliance revenues

--(--)

190.00M(0.24%)

271.00M(0.19%)

--(--)

Vfend

--(--)

187.00M(0.24%)

225.00M(0.15%)

267.00M(0.62%)

270.00M(0.67%)

346.00M(0.87%)

392.00M(0.96%)

Sutent

--(--)

180.00M(0.23%)

347.00M(0.24%)

673.00M(1.57%)

819.00M(2.03%)

936.00M(2.35%)

1.05B(2.57%)

Nimenrix

--(--)

179.00M(0.23%)

268.00M(0.18%)

193.00M(0.45%)

221.00M(0.55%)

230.00M(0.58%)

184.00M(0.45%)

Mektovi

--(--)

174.00M(0.22%)

176.00M(0.12%)

155.00M(0.36%)

142.00M(0.35%)

49.00M(0.12%)

--(--)

Bicillin

--(--)

158.00M(0.20%)

146.00M(0.10%)

--(--)

Trumenba

--(--)

126.00M(0.16%)

123.00M(0.08%)

118.00M(0.28%)

112.00M(0.28%)

135.00M(0.34%)

--(--)

Trazimera

--(--)

91.00M(0.12%)

203.00M(0.14%)

--(--)

Vaccines-Prevnar 13/Prevenar 13

--(--)

5.27B(12.31%)

5.85B(14.52%)

5.85B(14.65%)

5.80B(14.21%)

Hospital-All other Hospital

--(--)

2.41B(5.63%)

2.44B(6.05%)

2.23B(5.57%)

2.58B(6.33%)

PFIZER CENTREONE

--(--)

1.73B(4.04%)

926.00M(2.30%)

810.00M(2.03%)

--(--)

Internal Medicine-All other Internal Medicine

--(--)

1.71B(3.98%)

1.76B(4.36%)

2.02B(5.05%)

2.65B(6.49%)

Chantix/Champix

--(--)

398.00M(0.93%)

919.00M(2.28%)

1.11B(2.77%)

1.08B(2.66%)

Toviaz

--(--)

238.00M(0.56%)

252.00M(0.63%)

250.00M(0.63%)

271.00M(0.66%)

hospita-precedex

--(--)

177.00M(0.41%)

260.00M(0.65%)

155.00M(0.39%)

213.00M(0.52%)

Hospital-Zyvox

--(--)

173.00M(0.40%)

222.00M(0.55%)

251.00M(0.63%)

236.00M(0.58%)

Inflammation & Immunology (I&I)-All other I&I

--(--)

134.00M(0.31%)

121.00M(0.30%)

167.00M(0.42%)

192.00M(0.47%)

Rare Disease-All other Rare Disease

--(--)

115.00M(0.27%)

120.00M(0.30%)

129.00M(0.32%)

170.00M(0.42%)

Vaccines-All other Vaccines

--(--)

74.00M(0.17%)

42.00M(0.10%)

73.00M(0.18%)

206.00M(0.50%)

Consumer Healthcare Business

--(--)

2.08B(5.22%)

3.59B(8.79%)

Hospital-Pfizer CentreOne

--(--)

755.00M(1.85%)

Hospital-EpiPen

--(--)

303.00M(0.74%)

Hospital-Panzyga

--(--)

39.00M(0.10%)

地区

营业收入

占比

年报

年报

单季报

United States

Developed Markets

Emerging Markets

Developed Europe

Developed Rest of World

All Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

37.08B(59.25%)

38.69B(60.81%)

28.14B(35.64%)

43.32B(31.18%)

29.75B(36.59%)

21.45B(51.51%)

20.33B(49.69%)

20.12B(49.28%)

26.03B(49.53%)

26.37B(49.92%)

21.70B(44.43%)

19.07B(38.45%)

20.27B(39.30%)

21.31B(38.99%)

25.28B(41.41%)

Developed Markets

16.19B(25.87%)

16.06B(25.24%)

20.91B(26.48%)

40.53B(29.17%)

--(--)

Emerging Markets

9.31B(14.88%)

8.88B(13.95%)

10.50B(13.29%)

17.32B(12.47%)

20.70B(25.47%)

8.37B(20.10%)

8.83B(21.58%)

8.62B(21.11%)

11.40B(21.69%)

10.42B(19.73%)

11.14B(22.80%)

11.50B(23.18%)

11.22B(21.76%)

10.84B(19.84%)

10.12B(16.57%)

Developed Europe

--(--)

11.65B(14.75%)

21.98B(15.82%)

18.34B(22.56%)

7.79B(18.70%)

7.73B(18.90%)

8.00B(19.59%)

8.51B(16.19%)

9.31B(17.62%)

9.71B(19.88%)

11.72B(23.62%)

11.74B(22.76%)

12.54B(22.95%)

15.22B(24.94%)

Developed Rest of World

--(--)

7.76B(9.83%)

15.78B(11.36%)

12.51B(15.38%)

4.04B(9.69%)

4.02B(9.83%)

4.09B(10.02%)

6.61B(12.58%)

6.73B(12.74%)

6.30B(12.89%)

7.31B(14.74%)

8.35B(16.18%)

9.96B(18.22%)

10.42B(17.08%)

All Other

--(--)

1.00M(--)

--(--)